Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment

We report results in a 77-year-old male patient with visual loss from long-standing serpiginous choroidopathy treated with bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and the largest...

Full description

Bibliographic Details
Main Authors: Jeffrey N Weiss, Susan C Benes, Steven Levy
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Neural Regeneration Research
Subjects:
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=9;spage=1512;epage=1516;aulast=Weiss
_version_ 1818520120083873792
author Jeffrey N Weiss
Susan C Benes
Steven Levy
author_facet Jeffrey N Weiss
Susan C Benes
Steven Levy
author_sort Jeffrey N Weiss
collection DOAJ
description We report results in a 77-year-old male patient with visual loss from long-standing serpiginous choroidopathy treated with bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and the largest ophthalmology stem cell study registered at the National Institutes of Health to date (ClinicalTrials.gov Identifier: NCT01920867). Eight months after treatment by a combination of retrobulbar, subtenon, intravitreal and intravenous injection of BMSC, the patient′s best corrected Snellen acuity improved from 20/80 - to 20/60 +1 in the right eye and from 20/50 - to 20/20 -3 in the left eye. The Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity continued to improve over the succeeding 8 months and the optical coherence tomography macular volume increased. The increases in visual acuity and macular volume are encouraging and suggest that the use of BMSC as provided in SCOTS may be a viable approach to treating serpiginous choroidopathy.
first_indexed 2024-12-11T01:33:07Z
format Article
id doaj.art-f1263abd7c394bdbae61dd9cafdde91f
institution Directory Open Access Journal
issn 1673-5374
language English
last_indexed 2024-12-11T01:33:07Z
publishDate 2016-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Neural Regeneration Research
spelling doaj.art-f1263abd7c394bdbae61dd9cafdde91f2022-12-22T01:25:19ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742016-01-011191512151610.4103/1673-5374.191229Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatmentJeffrey N WeissSusan C BenesSteven LevyWe report results in a 77-year-old male patient with visual loss from long-standing serpiginous choroidopathy treated with bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and the largest ophthalmology stem cell study registered at the National Institutes of Health to date (ClinicalTrials.gov Identifier: NCT01920867). Eight months after treatment by a combination of retrobulbar, subtenon, intravitreal and intravenous injection of BMSC, the patient′s best corrected Snellen acuity improved from 20/80 - to 20/60 +1 in the right eye and from 20/50 - to 20/20 -3 in the left eye. The Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity continued to improve over the succeeding 8 months and the optical coherence tomography macular volume increased. The increases in visual acuity and macular volume are encouraging and suggest that the use of BMSC as provided in SCOTS may be a viable approach to treating serpiginous choroidopathy.http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=9;spage=1512;epage=1516;aulast=Weissserpiginous choroidopathy; serpigionous choroiditis; geographic helicoid peripapillary chroidopathy; retina; macula; stem cell therapy; uveitis
spellingShingle Jeffrey N Weiss
Susan C Benes
Steven Levy
Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
Neural Regeneration Research
serpiginous choroidopathy; serpigionous choroiditis; geographic helicoid peripapillary chroidopathy; retina; macula; stem cell therapy; uveitis
title Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
title_full Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
title_fullStr Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
title_full_unstemmed Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
title_short Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
title_sort stem cell ophthalmology treatment study scots improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment
topic serpiginous choroidopathy; serpigionous choroiditis; geographic helicoid peripapillary chroidopathy; retina; macula; stem cell therapy; uveitis
url http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=9;spage=1512;epage=1516;aulast=Weiss
work_keys_str_mv AT jeffreynweiss stemcellophthalmologytreatmentstudyscotsimprovementinserpiginouschoroidopathyfollowingautologousbonemarrowderivedstemcelltreatment
AT susancbenes stemcellophthalmologytreatmentstudyscotsimprovementinserpiginouschoroidopathyfollowingautologousbonemarrowderivedstemcelltreatment
AT stevenlevy stemcellophthalmologytreatmentstudyscotsimprovementinserpiginouschoroidopathyfollowingautologousbonemarrowderivedstemcelltreatment